LNA-Modified siRNA Duplexes for Nuclease Resistance and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current siRNA analogues face challenges with biostability, nuclease resistance, cellular uptake, and tissue distribution, limiting their effectiveness as therapeutic agents, particularly in cancer treatment and Severe Acute Respiratory Syndrome (SARS).
Innovation Solution
Development of double-stranded siRNA compounds incorporating locked nucleic acid (LNA) monomers, which enhance biostability, nuclease resistance, and cellular uptake by stabilizing the siRNA duplex and improving tissue distribution.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemically modified RNA residues are introduced into siRNA strands to increase stability, then biostability and nuclease resistance are improved, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent applies parameter changes by systematically varying the degree and position of LNA monomer incorporation into siRNA strands. Different embodiments test varying numbers of LNA monomers (from 1 to multiple per strand) at different positions, optimizing the balance between stability enhancement and manufacturing complexity. This allows tuning of the modification parameter to achieve desired biostability while controlling complexity.
Solution Approach 2:
The patent employs composite materials by creating hybrid nucleic acid structures that combine natural RNA residues with chemically modified LNA residues. This composite approach leverages the beneficial properties of both components: the biological compatibility of natural RNA and the enhanced stability of LNA modifications, achieving improved biostability while managing manufacturing complexity through standardized synthesis protocols.
2Reliability
If LNA monomers are incorporated into siRNA strands to enhance nuclease resistance, then durability in biological media is improved, but cellular uptake efficiency may be affected
Solution Approach 1:
The patent applies local quality by strategically positioning LNA monomers at specific locations within the siRNA strands rather than uniform distribution. The invention tests and optimizes the placement of LNA monomers at different positions (e.g., 5' end, 3' end, or internal positions) to achieve nuclease resistance while preserving regions that facilitate cellular uptake. This localized modification approach allows differential optimization of stability and uptake properties.
Solution Approach 2:
The patent applies partial action by incorporating a limited number of LNA monomers (partial modification) rather than complete conversion of all residues. This partial incorporation strategy allows the siRNA to retain sufficient natural RNA character for cellular recognition and uptake while gaining adequate nuclease resistance from the modified portions, balancing both requirements.
3Reliability
If siRNA duplex stability is increased through chemical modifications, then gene silencing effectiveness is improved, but tissue distribution and delivery efficiency may be reduced
Solution Approach 1:
The patent applies dynamics by creating siRNA duplexes with optimized melting temperatures through controlled LNA incorporation. The dynamic balance between duplex stability and flexibility is achieved by adjusting the number and position of LNA monomers, allowing the molecule to maintain stability for effective gene silencing while retaining sufficient flexibility for proper folding, cellular entry, and tissue distribution.
Solution Approach 2:
The patent applies parameter changes by systematically varying the LNA monomer content and positioning to optimize the melting temperature and structural properties of the siRNA duplex. This parameter optimization allows tuning of the stability-delivery trade-off, achieving sufficient duplex stability for gene silencing effectiveness while maintaining parameters favorable for tissue distribution and delivery efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The LNA-modified siRNA analogues demonstrate improved stability, nuclease resistance, and enhanced targeting capabilities, leading to effective gene silencing and therapeutic potential in cancer and SARS treatment.
Implementation Method 1
double-stranded compound comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides
Implementation Method 2
the compounds disclosed herein has improved properties compared to non-modified siRNAs... increased stability is also induced to the proximate native RNA residues
Data Source
AI summary
The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.